Latest Conference Articles

Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.

Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.

Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.

The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.

Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across 3 cohorts in resectable locally advanced HNSCC.

William Phillips, MD, discusses real-world findings on RET inhibitor dose reductions and clinical outcomes in advanced RET fusion–positive NSCLC.

Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.

Daniel Boiarsky, MD, discusses tumor-associated macrophages and CD24 expression in patients with metastatic NSCLC.

Lyudmila A. Bazhenova, MD, discusses the current state and future direction of antibody-drug conjugate development in lung cancer.

Dostarlimab monotherapy produced a 27% response rate in PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma

Narjust Florez, MD, discusses how the agenda for the Bridging the Gaps in Lung Cancer meeting evolves year to year based on emerging data and community feedback.

Noura Choudhury, MD, discusses how resistance mechanisms to tarlatamab-dlle could inform sequencing decisions in small cell lung cancer.

Jonathan Wesley Riess, MD, MS, discusses the evolving landscape of KRAS inhibitors, including the distinction between KRAS(OFF) and (ON) inhibitors.

Edward S. Kim, MD, MBA, discusses the purpose and value of the Bridging the Gaps in Lung Cancer meeting.

Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

A post hoc analysis of LITESPARK-005 found that higher baseline and improved-on-treatment QOL scores tracked with lower risk of disease progression and death.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.

Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.

Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.

Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.

Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.

Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.

Xiuning Le, MD, PhD, discusses treatment selection among targeted therapies for HER2-mutant NSCLC.

David Gerber, MD, discusses the evolution of ALK TKIs and the central nervous system toxicity tradeoffs seen with later-generation agents in NSCLC.

New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.